70results about How to "Reduce or avoid side effects" patented technology

The invention discloses a method for preparing novel F level high speed polyurethane enamelled wire paint, wherein the hydroxyl preparation consists of, using organic titanium-antimony complex as catalyst, substituted aromatic dibasic alcohol as adjuvant, tri (alpha-ethoxyl) isocyanate as modifier for polycondensation 6 hours at 130-200 deg. C under atmosphere pressure, and closed constituent preparation consists of using substituted aromatic tertiary amine as catalyst, thus reacting 4,4'-methyl diphenylene diisocyanate with trimethylolpropane, and obtaining a proportion of isocyanate urea rings with thermotolerant structure.

The invention discloses a method for preparing novel B level high speed polyurethane enamelled wire paint, wherein the hydroxyl preparation consists of, using organic titanium-antimony complex as catalyst, substituted aromatic dibasic alcohol as adjuvant, for polycondensation 5 hours at 130-200 deg. C under atmosphere pressure, and closed constituent preparation consists of using substituted aromatic tertiary amine as catalyst, thus reacting 44'-methyl diphenylene diisocyanate with trimethylolpropane, and obtaining a proportion of isocyanate urea rings with thermotolerant structure.

The invention relates to the field of medical polymers, and discloses a preparation method of a controlled-release hydrogel with photo-thermal treatment and wound repair functions. The method comprises the following steps of: firstly, modifying dopamine on alginic acid to ensure that an o-diphenol side group is arranged on a molecular chain of the alginic acid, and simultaneously preparing coppersulfide @ melanin-PEG @ dopamine nanoparticles with good photo-thermal performance and radiotherapy effect; and then adding the copper sulfide @ dopamine nanoparticles into a dopamine-modified alginicacid solution, adding astragaloside with the function of promoting wound healing into the solution at the same time, and forming gel through a catalytic cross-linking system of horseradish peroxidaseand hydrogen peroxide. The hydrogel has good controlled release performance and can play a role in reducing administration dosage and reducing or avoiding toxic and side effects. The hydrogel prepared by the method has good biocompatibility, can be used for treating cancer cells by utilizing photo-thermal performance and radiotherapy, and can be combined with the astragaloside for promoting postoperative wound healing.

The invention provides a method for preparing an anthracycline antitumor antibiotic oleic acid compound and an oil-water double phase for preparing the compound and albumin, and the anthracycline antitumor antibiotic oleic acid compound is prepared into an albumin nanoparticle preparation. The albumin nanoparticle preparation prepared by the method is little in using amount of auxiliary materials, high in medicine-carrying dose and high in stability, and a preparation process is simple and is suitable for large-scale industrial production; and the albumin nanoparticle preparation has the tumor targeting and good clinical application value.

The invention relates to a cough syrup and a method for preparing the same, which belong to the field of Chinese traditional medicines. The cough syrup consists of fourteen Chinese traditional medicines including herba ephedrae, apricot kernel, plaster stone, liquorice, semen coicis, herba schizonepetae, aster, radix stemonae, dried orange peel, radix cynanchi, balloon flower, honeysuckle, bark of white mulberry root and loquat leaf which are decocted or soaked with water to obtain a thick juice to be concentrated, are added or not added with honey (or rock candy), and are prepared into syrups. The cough syrup is taken orally to treat respiratory tract infections, and has the efficacies of clearing away heat and toxic material, diminishing inflammation, reducing and expectorating phlegm, and relieving cough and asthma. Compared with the prior similar drugs, the cough syrup has the characteristics of low cost, simple and convenient preparation, shortened treatment period, no toxic side effects, and suitability for both the young and the old.

Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation of a drug for the prevention and / or treatment of a central nervous system disease.

The invention discloses a method for extracting and synthesizing thymus microcapsule sustained release needle by PLGA which comprises the following steps, (1) carrying out thymolysis in small amount of water, obtaining inner layer water phase, (2) dissolving the PLGA into organic solution, obtaining organic phase, (3) dispersing the inner layer aqueous phase into organic phase during high-speed agitating, obtaining water-in-oil type emulsion (emulsion 1), (4) charging emulsion 1 into outer layer aqueous phase containing dispersing agent, agitating to form double layer emulsion, obtaining water / oil / water composite emulsion, (5) volatilizing the organic solvent and curing the polymeric layer, forming solid microsphere, thus coating the thymus gland at the center of the microsphere.

The invention provides a compatible composition for treating rheumatoid arthritis and a preparation method thereof. The prescription consists of tripterygium wilfordii and peonies, wherein the ratio in part by weight of tripterygium wilfordii to peonies in combination is 0.01-100:1. The effect of the composition for treating rheumatoid arthritis is better than that of tripterygium wilfordii preparations used alone and is better than that of white peony total glycosides used together with tripterygium wilfordii polyglycosides for treating rheumatoid arthritis. Meanwhile, toxic-side effects caused by using the tripterygium wilfordii preparations alone can be greatly reduced or avoided.

The invention discloses a hydrogenation process for hydrogen peroxide production. The process comprises the following steps: (1) in a hydrogenation process for producing hydrogen peroxide by an anthraquinone process, arranging a hydrogenation tower I, a hydrogenation tower II and a hydrogenation tower III, and feeding hydrogen gas in three channels, i.e., hydrogen gas I, hydrogen gas II and hydrogen gas III; (2) mixing and dissolving working fluid feed and the hydrogen gas I in high-pressure gas dissolving equipment, and then, enabling the solution to enter the hydrogenation tower I for a first-stage hydrogenation reaction; (3) mixing and dissolving effluent of the first-stage hydrogenation reaction and the hydrogen gas II in the high-pressure gas dissolving equipment, and then, enabling the solution to enter the hydrogenation tower II for a second-stage hydrogenation reaction; (4) mixing and dissolving effluent of the second-stage hydrogenation reaction and the hydrogen gas III in the high-pressure gas dissolving equipment, and then, enabling the solution to enter the hydrogenation tower III for a third-stage hydrogenation reaction; and (5) enabling a material obtained after the third-stage hydrogenation reaction to flow out, carrying out gas-liquid separation, and going to next procedure. According to the process, through controlling the proportion of dissolved hydrogen, not only can a relatively high hydrogenation effect be achieved, but also minimal anthraquinone degradation products are obtained, so that the improvement on product concentration and device scale and the lowering of the consumption of a catalyst and anthraquinone are facilitated.

The invention belongs to the technical field of catalyst processing, particularly relates to a catalyst for synthesizing succinic acid through water-phase catalytic hydrogenation, and further discloses a preparation method of the catalyst and application of the catalyst for synthesizing succinic acid through catalytic hydrogenation. The invention discloses a catalyst for synthesizing succinic acidthrough water-phase catalytic hydrogenation, and further discloses a method for synthesizing succinic acid through water-phase hydrogenation by directly catalyzing a maleic acid aqueous solution through the catalyst, wherein an intermediate product maleic acid aqueous solution generated in the existing maleic anhydride synthesis process is directly used as a raw material to directly perform aqueous phase catalytic hydrogenation to synthesize succinic acid, so that the step of post-treatment from maleic acid to a maleic anhydride product is omitted, continuous large-scale production can be realized, the production process of succinic acid is greatly simplified, and the production cost is effectively saved. The catalyst is also completely suitable for a process of preparing succinic acid bytaking an aqueous solution obtained by dissolving maleic anhydride as a raw material.

The invention discloses a repetitive transcranial magnetic stimulation method capable of carrying out multi-stimulation-target focusing. The repetitive transcranial magnetic stimulation method specifically comprises the following steps of: 1) obtaining multiple-modality brain magnetic resonance image data of a subject; 2) determining a target deep effect brain area; 3) determining a plurality of superficial cortex stimulation brain areas connected with the effect brain area; 4) measuring individualized motor evoked potential, determining an individualized motor threshold, and setting the stimulation intensity of repetitive transcranial magnetic stimulation capable of carrying out the multi-stimulation-target focusing; 5) confirming a stimulation total quantity, and guaranteeing that each stimulation target equally divides the stimulation total quantity; and 6) carrying out individualized magnetic resonance image data navigation based repetitive transcranial magnetic stimulation capableof carrying out the multi-stimulation-target focusing, and independently stimulating selected stimulation targets in sequence. By use of the stimulation method, through connection between a pluralityof stimulation targets and the deep effect brain area, the neural activity of the deep effect brain area is regulated and controlled through targeted focusing to achieve a treatment effect.

The invention provides a preparation method for a composite polysulfone membrane, belonging to the field of composite materials. The preparation method comprises the following steps: providing a basemembrane which is a dopamine in-situ polymerization doped polysulfone membrane and has a semi-interpenetrating type network structure; and crosslinking a chitosan copper complex onto the surface of the above-mention base membrane in a pulsed electric field environment so as to obtain the composite polysulfone membrane, wherein the above-mentioned composite polysulfone membrane has a contact angleof 45 degrees to 80 degrees, a pure water flux of 600 to 1250 L / m2.h and a rejection rate of at least 90%. The preparation method provided by the invention can increase the membrane pore size and water flux, limits membrane structure and mechanical properties from being destroyed due to agglomeration and water absorption of dopamine, reduces the attachment amount of organic substances in membranepores, improves membrane hydrophilicity and the rate of retention, reduces the decay rate of membrane pore flux and the increase coefficient of membrane resistance to improve pollution resistance, andreduces the replacement frequency of the composite membrane to save treatment cost; and the composite polysulfone membrane is used in the fields of marine aquaculture wastewater treatment, marine sterilization, red tide prevention and treatment, etc.

The invention discloses a medical suspended preparation and a preparation method thereof. The medical suspended preparation is used for treating and preventing diseases or regulating physiological functions through medical information without contacting human or animal body skins. The basic structure of the medical suspended preparation is composed of a medicament bank (1), a container (4) and a connecting piece (5). Contents (2) are medicaments having pharmacological activities. When the preparation is used in treatment, no medicinal material matters enter a human or animal body, so safety problem as well as the simulation of oral preparations to the gastrointestinal tract, the first-pass effect of the gastrointestinal tract, the drawbacks of pains, cross-infection risks and injection and infusion reactions of injections, the simulation and damage of transdermal patchs to skin, the damage of adhesive to skin, and the like are avoided. The product can be used repeatedly, so the consumption of medicaments is reduced greatly, medicament resources are saved, environmental pollution caused by pharmaceutical industry is reduced greatly, and ecological is protected. The preparation is simple, convenient and safe to use and is particularly suitable for treating the aged and weak, children, people with mental retardation and animals.

The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.

The invention relates to combined wave treatment equipment and treatment system. The combined wave treatment equipment comprises an ultrasonic wave generation unit (10), an impact wave generation unit(20) and a combined wave generator (30), wherein the ultrasonic wave generation unit (10) is used for generating therapeutic ultrasonic waves; the impact wave generation unit (20) is used for generating therapeutic impact waves; the combined wave generator (30) is coupled with the ultrasonic wave generation unit (10) and the impact wave generation unit (20) respectively and is used for combiningthe therapeutic ultrasonic waves and the therapeutic impact waves into combined waves and applying the combined waves to a part to be treated. By adopting the combined wave treatment equipment and treatment system, the treatment effect can be improved and the side effect of treatment waves is reduced.

The present invention relates to a docetaxel nanometer lipid injection. The invention also relates to a method for preparing the docetaxel nanometer lipid injection. The invention further relates to the application of the docetaxel nanometer lipid injection for preparing medicament for treating a tumor. The nanometer preparation of the invention is capable of prolonging the medicament action time, conveying the medicament with a target, reducing the administration dose under the precondition of ensuring the medicament action, alleviating or avoiding medicament toxin and side effects, improving the medicament action stability, and being benefited for the medicament storage, thus it is capable of implementing the development of the medicament which has advantages in the aspects of a high yield, automatization, large scale, low cost, convenient carry and storage, small dose and low side-effect.

The invention relates to a preparation method of 2-methyl-1-(4-substituted phenyl)-2-morpholinyl-1-acetone. The preparation method comprises two steps of epoxidation reaction and morpholine substitution reaction, wherein in the morpholine substitution reaction, a proper amount of an auxiliary agent is added, and the auxiliary agent is selected from at least one of water, a strong-acid weak-alkalisaline solution and a strong-alkali weak-acid saline solution, so that the ring opening rate and the ring opening selectivity in the morpholine substitution reaction process can be obviously improved,and the overall reaction rate and yield are further improved, according to the method, the problem that subsequent catalysts are difficult to filter, recycle and purify due to the fact that catalystssuch as carclazyte need to be added in the traditional process is solved, the high-purity 2-methyl-1-(4-substituted phenyl)-2-morpholinyl-1-acetone can be obtained more easily, the process cost and the aftertreatment operation risk are reduced, and the economic benefit is improved.

The invention discloses a preparation method of a calcium phosphate-rapamycin composite drug, a making method of a drug coating balloon and the drug coating balloon. Through compounding of calcium phosphate and rapamycin, the stability of a rapamycin structure can be improved, continous release of the rapamycin structure is facilitated in vivo, the adhesion capacity of rapamycin on the surface of the balloon and the infiltration capacity of rapamycin in tissue are improved, the retention time of the drug after administration is prolonged, the inhibition effect of rapamycin on cells is improved, so that the treatment effect of rapamycin on vascular restenosis diseases is enhanced, the solubility and stability of the drug can be improved by the nano-material coating, the use dosage of the drug is further reduced, and toxic and side effects are relieved or avoided; and due to the slow release effect of the nanoparticles, the peak-valley phenomenon of the blood concentration can be eliminated, a certain treatment concentration is maintained, and adverse reactions caused by instantaneous overhigh blood concentration are effectively prevented; and the nanoparticles can prolong the retention time of the drug in the circulation system and improve the treatment level of the drug.

The invention relates to the field of biomedical high polymer materials and discloses a preparation method of controlled release hydrogel used for tumor postoperative chemotherapy magnetic-thermal andphoto-thermal combined treatment. Carboxymethyl chitosan-dopamine with good biocompatibility is utilized to be loaded with ferroferric oxide@melanin-PEG@dopamine nano particles with good photo-thermal performance and magnetic-thermal performance, and indocyanine green with photo-thermal performance and photodynamic performance, and thus the hydrogel with a controlled release function for tumor postoperative magnetic-thermal, photo-thermal and photodynamic combined treatment. The hydrogel can conduct photo-thermal, photodynamic and magnetic-thermal treatment on postoperative tumor parts. Meanwhile, the hydrogel has good controlled release performance, the effects of decreasing the drug administration dosage, and reducing or avoiding toxic and side reaction are realized, the stability of adrug is improved, and storage is facilitated; and some new drug administration approaches can be established.

A lovastatin acid and lovastatin acid salt production processes and their application, to solve the problem of significantly toxicity of lactone form lovastatin, such as liver injury and causing muscle pain and elevating transaminase. The invention uses 95% ethanol and NaOH (13 ~ 100:8 that m lactone structure: mNaOH) to modulate into alkaline solution, makes lactone lovastatin powder dissolved in solution, and uses HCl adjust PH to obtain the acid form and salt state compounds, widely used for lipid drug.

The invention discloses a medicine composition mainly containing oral glucocorticoid and an oral bronchodilator, as well as application thereof in preparing medicines for treating chronic obstructive pulmonary diseases (COPD) and bronchial asthma, which belongs to the technical field of medicine preparations. The oral glucocorticoid contained in the medicine composition is prednisone, prednisolone or methylprednisolone, and the oral bronchodilator is formoterol, clenbuterol or euphylline. The curative effect of the composition for treating the COPD or the bronchial asthma is better than that of separately using the two composition ingredients one after another, and the composition has the characteristics of synergistic action and low cost. Thus, the combination preparation of the oral glucocorticoid and the oral bronchodilator is of great significance to the treatment and the prevention of the COPD and the bronchial asthma of patients of lower income groups in wide rural and urban areas in China.

The invention relates to the field of pharmacy, and particularly provides application of rutin medicines to preparing medicines for preventing or treating medicine-induced cardiac toxicity. The rutin medicines comprise rutin or troxerutin, and the medicine-induced cardiac toxicity refers to cardiac toxicity due to application of antitumor anthracycline medicines and preferably refers to cardiac toxicity due to application of pirarubicin or epirubicin. The application has the advantages that the cardiac toxicity of subjects due to the anthracycline medicines can be effectively prevented or treated by the medicines, and toxic and side effects of the medicines can be lowered.

The invention belongs to the technical field of veterinary medicament preparations, and particularly discloses a long-acting compound sulfamonomethoxine injection and a preparation method thereof. The long-acting compound sulfamonomethoxine injection is prepared from the following raw materials in percentage by weight: 8-12 percent of sulfamonomethoxine (SMM), 1-3 percent of trimethoprim (TMP), 40-55 percent of propylene glycol, 8-12 percent of ethanol, 1-3 percent of cholamine, 1-4 percent of benzyl alcohol, 1-4 percent of polyvinylpyrrolidone (PVP) and the balance of water for injection. In the long-acting compound sulfamonomethoxine injection, polyvinylpyrrolidone serving as a sustained-release material is added and is uniformly dispersed into a treatment medicament, so that the medicament can be released slowly after entering an animal body, the half-life period of the medicament is prolonged, effective blood concentration is maintained for a long time, side effects caused by 'peak valley' fluctuation of the blood concentration are reduced or avoided, and the aims of high efficiency, long-acting property and stability are fulfilled.

The invention provides tripterine nanometer lipid injection and a method for preparing same, wherein the nanometer lipid injection contains a active component of tripterine and a self-emulsifying medicament releasing system made from ester copolymer and phospholipid derivates, the nanometer lipid injection is oil in water type (O / W) microparticles, particle diameters of the nanometer microparticles is smaller than 200nm, and the medicament-carrying amount of the nanometer microparticles is large than 98%. The tripterine nanometer lipid injection provided by the invention is a new formulation, is an anti-tumor nanometer injection product, can substantially raise bioavailability of the medicaments in human body, and increase stability of the medicaments, and the preparation method is simple and suitable for large-scale production. The tripterine nanometer lipid injection provided by the invention can be applied to treat rheumatoid, senile dementia and tumor, and especially has a large market prospect for preventing and treating cancer.

Relating to the field of pharmacy, the invention in particular provides an anti-tumor pharmaceutical composition containing a rutin drug. The pharmaceutical composition is composed of a rutin drug and an anthracycline drug, wherein the rutin drug is rutin or troxerutin, and the anthracycline drug is epirubicin or pirarubicin. The pharmaceutical composition provided by the invention has better antitumor effect than anthracycline drugs, also effectively alleviates or avoids the cardiac toxicity of patients, and reduces the toxic and side effect of drugs.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a method for synthesizing succinic acid through low-cost continuous water-phase catalytic hydrogenation.According to the method for synthesizing succinic acid through low-cost continuous water-phase catalytic hydrogenation, a fixed bed catalytic mode is adopted, an intermediate product maleic acid aqueous solution generated in an existing maleic anhydride or maleic anhydride synthesis process is directly used as a raw material for directly carrying out water-phase catalytic hydrogenation to synthesize succinic acid, so that the step of post-treatment from maleic acid to a maleic anhydride product is omitted, and continuous large-scale production can be realized; and the method has the advantages of cheap raw materials, recyclable water in the preparation process, almost no three-waste pollution in the whole preparation process, great simplification of the succinic acid production process, and effective saving of the production cost.

The invention relates to a medicinal control release nanometer and method for making same, in particular a retinoic acid release control nanomicrosphere and its preparation method, the constituents of the composition are polylactic acid (PLA), vitamin A acid (RA) and gelatin aqueous solution.

The invention provides a cefuroxime sodium pharmaceutical composition and a preparation method thereof, relating to the field of a pharmaceutical preparation and a preparation method thereof. The invention mainly solves the problems of high dosage of single cefuroxime sodium and metronidazole preparation, poor treatment effect after combination, and great side effect in the prior art. The pharmaceutical composition comprises cefuroxime sodium and metronidazole lipid microspheres in a weight ratio of 100:3-100:10, wherein the weight of the metronidazole lipid microspheres is metered on the basis of on metronidazole; and when the pharmaceutical composition is prepared into a powder injection, the pH value of the water solution of the pharmaceutical composition is 6.5-7.0. The pharmaceutical composition powder injection provided by the invention has high curative effect, and can reduce the consumption of the metronidazole by more than 80%, thereby greatly relieving or avoiding the toxic and side effects of the metronidazole, especially digestive tract reactions, including nausea, vomit, inappetence, abdominal colic and neurotoxicity, and lowering the incidence rate of adverse reactions.

The invention relates to a medicinal control release nanometer and method for making same, in particular a retinoic acid release control nanomicrosphere and its preparation method, the constituents of the composition are polylactic acid (PLA), vitamin A acid (RA) and gelatin aqueous solution.

The invention relates to the field of biomedical polymer materials and discloses a preparation method of a controlled release hydrogel for tumor postoperative radiotherapy in combination with photothermal-photodynamic therapy. The hydrogel which has a controlled release function and is used for the tumor postoperative radiotherapy in combination with the photothermal-photodynamic therapy is obtained by adopting silk fibroin loaded with copper sulfide@melanin-PEG@dopamine nanoparticles and a photosensitizer 5-aminolevulinic acid, wherein the silk fibroin has good biocompatibility, and the copper sulfide@melanin-PEG@dopamine nanoparticles have a great photothermal property and a good radiotherapy function. The hydrogel can be used for performing photothermal therapy, photodynamic therapy andradiation therapy on a postoperative tumor part. At the same time, the hydrogel has a good controlled release property and can achieve the effects of reducing the drug delivery dosage and reducing oravoiding toxic and side effects. The stability of drugs is improved, and the hydrogel is convenient to store; some new drug delivery routes can be established.